Details of the Drug Combination

General Information of Drug Combination (ID: DCDU3AL)

Drug Combination Name
Clomiphene Citrate Piperacetazine
Indication
Disease Entry Status REF
Lymphoid neoplasm Investigative [1]
Component Drugs Clomiphene Citrate   DMS51VC Piperacetazine   DMGQU0Y
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: Mak
Zero Interaction Potency (ZIP) Score: 9.863
Bliss Independence Score: 11.061
Loewe Additivity Score: 6.999
LHighest Single Agent (HSA) Score: 17.29

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Clomiphene Citrate
Disease Entry ICD 11 Status REF
Female infertility GA31.Z Approved [2]
Clomiphene Citrate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Modulator [3]
------------------------------------------------------------------------------------
Clomiphene Citrate Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [4]
------------------------------------------------------------------------------------
Indication(s) of Piperacetazine
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [2]
Piperacetazine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Modulator [3]
------------------------------------------------------------------------------------
Piperacetazine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [5]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
5 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.